nContact’s Hybrid Convergent Procedure Takes Aim At Persistent AF
Executive Summary
Positive clinical results were presented at this year’s Boston AF Symposium on nContact Surgical Inc.’s minimally invasive Convergent Procedure, a combined epicardial and endocardial approach for treating patients with persistent atrial fibrillation, who currently have no good treatment options outside of open surgery. According to the company, about 50% of the entire AF population could potentially benefit from the Convergent Procedure, representing a potential patient market of nearly $15 billion.
You may also be interested in...
New AF Ablation Tools Offer Promise Of Greater Efficacy, Durability
Novel arrhythmia mapping technologies, once they are clinically proven and validated, could change practice paradigms in the atrial fibrillation ablation space but in the meantime work continues on nearer-term advances that could make AF ablation more effective and durable. Three of the most promising – contact force sensing, endoscopic laser ablation, and atrial fibrosis imaging, from such companies as Endosense, Biosense Webster, CardioFocus, and Marrek – have recently achieved some important milestones in their journeys toward US market approval.
New Paradigms Brewing In Atrial Fibrillation Ablation
Groundbreaking new mapping technologies could shift the future direction of the $2.5 billion AF ablation market, as evidenced by presentations at this year’s HRS and EUROPACE meetings; with some compelling clinical data now on the books, the electrophysiologists who perform AF ablation are taking notice, as are investors and strategics operating in this space. Emerging companies at the heart of this shift include Topera Medical, CardioInsight Technologies, and Acutus Medical.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.